Harrow, Inc. (HROW) - Q3 2024 10-Q Summary
Business Context and Reporting Period
This summary covers the quarterly period ended September 30, 2024. Harrow, Inc. is a leading eyecare pharmaceutical company engaged in the discovery, development, and commercialization of innovative ophthalmic products. The company operates two reportable segments: Branded (FDA-approved ophthalmic products) and ImprimisRx (ophthalmology-focused pharmaceutical compounding). As of November 12, 2024, there were approximately 35.6 million shares of common stock outstanding.
Key Financial Metrics
| Metric | Q3 2024 (3 Months) | Q3 2023 (3 Months) | YTD 2024 (9 Months) | YTD 2023 (9 Months) |
|---|---|---|---|---|
| Total Revenues | $49.26 million | $34.27 million | $132.78 million | $93.84 million |
| Gross Profit | $37.24 million | $24.20 million | $97.67 million | $65.50 million |
| Gross Margin | 75.6% | 70.6% | 73.5% | 69.8% |
| Net Loss | $(4.22) million | $(4.39) million | $(24.26) million | $(15.26) million |
| Diluted EPS | $(0.12) | $(0.13) | $(0.68) | $(0.48) |
| Cash and Equivalents | $72.60 million (as of Sept 30, 2024) | |||
| Total Debt (Net) | $186.06 million (as of Sept 30, 2024) |
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 44% year-over-year for Q3 2024, driven primarily by the Branded segment which grew 97% to $28.55 million. Key drivers include the launch of VEVYE and strong sales of IHEEZO.
- Operating Expenses: Selling, general, and administrative (SG&A) expenses rose significantly to $33.65 million in Q3 2024 (up from $21.03 million in Q3 2023) due to regulatory enhancements, transition costs for acquisitions, and headcount expansion to support growth.
- Investment Loss: The company recorded a $3.17 million loss on the sale of its investment in Eton Pharmaceuticals during the nine months ended September 30, 2024, compared to a gain in the prior year period.
- Segment Reporting: The company began reporting two distinct segments (Branded and ImprimisRx) starting in Q3 2024, whereas it previously operated as a single segment.
Outlook, Risks, and Unusual Items
- Subsequent Events (Debt & Milestone): In October 2024, the company drew down an additional $30 million under its Oaktree Loan facility to fund a $37 million milestone payment to Novartis for the commercial availability of TRIESENCE. Total principal drawn under the Oaktree Loan is now $107.5 million, with no additional availability remaining.
- Cybersecurity Incident: In November 2024, the company experienced a cybersecurity incident involving unauthorized access to an employee email account, resulting in the fraudulent diversion of company funds. Management believes the impact is immaterial, but the investigation is ongoing.
- Liquidity: Management believes current cash and cash equivalents ($72.6 million) are sufficient to sustain operations for at least the next 12 months. However, the company may need to seek additional financing for future acquisitions or strategic transactions.
- Legal Proceedings: A trial regarding copyright and trademark infringement claims against Ocular Science, Inc. began in November 2024 and is ongoing.
Investor Verification Checklist
- Debt Capacity: Verify the impact of the fully drawn Oaktree Loan ($107.5M) on future liquidity and the ability to service debt given the high interest rates (effective rate ~11%).
- Cybersecurity Impact: Monitor updates on the November 2024 cybersecurity incident to confirm the final financial loss and any potential regulatory penalties.
- Revenue Concentration: Note that a single customer accounted for 46% of total consolidated revenues in Q3 2024; assess the risk associated with this concentration.
- Product Launch Execution: Track the commercial performance of VEVYE and the re-launch of TRIESENCE as key growth drivers.
- Contingent Consideration: Review the $37 million contingent consideration payable recorded in Q3 2024 related to the Novartis asset purchase.